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Abstract 
Rationale: Subcellular Ca2+ indicators have yet to be developed for the myofilament where disease 
mutation, or small molecules may alter contractility through myofilament Ca2+ sensitivity. Here we 
develop and characterise genetically encoded Ca2+ indicators restricted to the myofilament to directly 
visualise Ca2 changes in the sarcomere. 
Objective: To produce and validate myofilament restricted Ca2+ imaging probes in an adenoviral 
transduction adult cardiomyocyte model using drugs that alter myofilament function (MYK-461, 
omecamtiv mecarbil and levosimendan) or following co-transduction of two established hypertrophic 
cardiomyopathy (HCM) disease causing mutants (cTnT R92Q and cTnI R145G) that alter 
myofilament Ca2+ handling. 
Methods and Results: When expressed in adult ventricular cardiomyocytes RGECO-TnT/TnI sensors 
localise correctly to the sarcomere without contractile impairment. Both sensors report cyclical 
changes in fluorescence in paced cardiomyocytes with reduced Ca2+ on and increased Ca2+ off rates 
compared with unconjugated RGECO. RGECO-TnT/TnI revealed changes to localised Ca2+ handling 
conferred by MYK-461 and levosimendan, including an increase in Ca2+ binding rates with both 
levosimendan and MYK-461 not detected by an unrestricted protein sensor. Co-adenoviral 
transduction of RGECO-TnT/TnI with HCM causing thin filament mutants showed that the mutations 
increase myofilament [Ca2+] in systole, lengthen time to peak systolic [Ca2+], and delay [Ca2+] release. 
This contrasts with the effect of the same mutations on cytoplasmic Ca2+, when measured using 
unrestricted RGECO where changes to peak systolic Ca2+ are inconsistent between the two mutations. 
These data contrast with previous findings using chemical dyes that show no alteration of [Ca2+] 
transient amplitude or time to peak Ca2+. 
Conclusions: RGECO-TnT/TnI are functionally equivalent. They visualise Ca2+ within the 
myofilament and reveal unrecognised aspects of small molecule and disease associated mutations in 
living cells.  
 
 
 
Key Words: Hypertrophic cardiomyopathy, Calcium, Contractility, Genetically encoded Ca2+ 
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Non-standard Abbreviations and Acronyms: 
CaM   Calmodulin 
CaMKII  Ca2+/calmodulin dependant kinase II 
cAMP   Cyclic AMP 
GECI   Genetically encoded calcium indicator 
GFP   Green fluorescent protein 
GPCM   Guinea pig cardiomyocyte 
HCM   Hypertrophic cardiomyopathy 
MOI   Multiplicity of infection 
NCX   Sodium calcium exchanger 
PLN   Phospholamban 
TnC   Troponin C 
TnI   Troponin I 
TnT   Troponin T 
RyR   Ryanodine Receptor 
SERCA  Sarco-endoplasmic reticulum ATPase 
SR   Sarcoplasmic reticulum 
T50   Time to 50% 
WT   Wild Type 
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Introduction 
The myofilament converts the chemical energy of ATP into mechanical energy, a process 
regulated by Ca2+. Mutations in myofilament components cause common (1:500) inherited conditions 
like hypertrophic cardiomyopathy (HCM)1,2, 3. HCM causing mutations produce hypercontractility, 
energetic compromise4-6 and change Ca2+ utilization within the cardiomyocyte. Altered intracellular 
Ca2+ may be directly proarrhythmic, causing sudden death, and activate hypertrophic signalling 
pathways that produce the cardiac hypertrophy, and premature heart failure, observed in HCM 
patients. Interestingly, increased myofilament Ca2+ affinity arises from different mutations7, 8. 
Prevalent thick filament mutations increase the Ca2+ sensitivity of contractility by altering acto-
myosin affinity and modifying conformational changes in the myosin motor domain9. Conversely, 
thin filament mutations in the regulatory components troponin T (TnT) and I (TnI) increase the 
affinity of troponin C (TnC) for Ca2+. Some consequences of trapping Ca2+ in the sarcomere by the 
introduction of Ca2+ sensitizing HCM mutations are known10-12. Briefly, raised myofilament Ca2+ 
binding produces secondary alterations in cytoplasmic and SR [Ca2+] in addition to altered 
activation/regulation of key Ca2+ handling proteins (e.g. Ryanodine Receptor, SERCA2a and 
phospholamban). Hypertrophic signalling via calcineurin/NFAT and ERK promotes cellular 
hypertrophy13. These factors, combined with altered mechanosensing14 and energetics2, 15, drive the 
stereotyped end-organ changes seen in patients. 
Ca2+ cycling changes in HCM are typically assessed using chemical Ca2+ dyes10, 11, 13. 
However, dyes are not spatially restricted 16-19 and thus report whole cell phenomena. The patch clamp 
technique20 can resolve subcellular Ca2+ events10, 11 but is technically challenging and low throughput. 
Genetically encoded calcium indicators (GECIs) offer an alternative strategy for Ca2+ assessment17, 19, 
and may be restricted to subcellular compartments by a defined sequence tag or protein fusion. 
Myofilament specific calcium probes remain elusive, in part due to the concern that the bulky 
30x40x70Å adducts of the smallest GECIs21 are unlikely to be tolerated by the paracrystalline 
sarcomeric environment22, 23 leading to perturbed function of the indicator, the fusion partner, or the 
cell. However, fluorescence resonance energy transfer-based cAMP indicators conjugated to 
myofilament proteins that do not affect cardiomyocyte contractility have been reported24. 
GECIs are available with different calcium sensor domains, tuned to different affinities, in a 
range of spectral hues. The CaM/M13 calcium sensor domain appears in most of the indicators 
successfully reported in cardiomyocytes, but not all GECIs work in all cardiac models17. For example, 
tools improved for neuronal applications may lose functionality in cardiac cells17 eg TN-XL25 and 
TN-XXL26. Subcellular targeting of GECIs within cardiomyocytes to probe Ca2+ in the SR27 and, by 
conjugation of GCaMP2.2 to FKBP12.6, Ca2+ efflux from the SR28 has been demonstrated. These 
probes visualise the Ca2+ store, but currently no equivalent tool to study Ca2+ at the myofilament, 
where Ca2+ regulates contraction exists.  
Since contractility underpins cardiac function there is interest in development of small 
molecule modulators of myofilament contractility22, 29-31. Importantly these agents should not affect 
Ca2+ handling, which may be pro-arrhythmic. Application of unrestricted, or myofilament localised, 
indicators may give greater mechanistic insight into this subclass of drugs, which include the myosin 
ATPase inhibitor MYK-46130, a novel therapy for hypertrophic cardiomyopathy, and levosimendan31 
a myofilament activator developed for heart failure.   
Here we produce, and characterize  myofilament localized Ca2+ sensors to directly visualize 
changes in Ca2+ flux at the myofilament occurring in response to small molecules or disease causing 
mutations. We reveal how two well characterised thin filament HCM causing mutations in cTnT 
(R92Q)4, 10, 32, 33 and cTnI (R145G)10, 34-36 are from a Ca2+ handling perspective mechanistically similar 
at the myofilament, but distinct in the cytoplasm. The combination of probes reveals biology 
previously inferred. The method increase scale, reduces animal use, and is compatible with existing 
imaging infrastructure and single cell protocols.  
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Materials and Methods 
Isolation of guinea pig left ventricular cardiomyocytes 
This investigation was approved by the Animal Welfare and Ethical Review Board at the 
University of Oxford and conforms to the UK Animals (Scientific Procedures) Act, 1986, 
incorporating Directive 2010/63/EU of the European Parliament. As described10, left ventricular 
cardiomyocytes were isolated from male (to prevent confounding effects of hormonal cycle) 
adolescent (400 g) guinea pig hearts by collagenase perfusion for 5 minutes then placed on a shaker 
for a further 10 minutes. Left ventricular cardiomyocytes (1.5x105 cells per ml) were incubated in 
ACCITT3 culture medium37 at 37°C and 5%CO2. 
Adenoviral Transduction 
RGECO-TnT (plus BamHI linker) and RGECO-TnI (plus XhoI linker) were cloned into a 
shuttle vector. RGECO and RGECO-TnI adenoviruses were generated, purified and titred by Welgen, 
Inc. (Worcester, MA, USA). RGECO-TnT, WT cTnT, cTnT R92Q, WT cTnI, and cTnI R145G 
adenoviruses were generated as described10. Immediately after isolation GPCMs were adenovirally 
co-transduced for 48 hours with RGECO (MOI=444) and either WT cTnT (795), cTnT R92Q (933), 
WT cTnI (795), or cTnI R145G (795). Co-transductions of RGECO-TnT (MOI=795) were with either 
WT cTnI (795), or cTnI R145G (1590). Co-transductions of RGECO-TnI (MOI=444) were with 
either WT cTnT (795) or cTnT R92Q (1493). 
Protein purification 
N- and C-terminal eGFP conjugates of human recombinant TnT, TnI and TnC were cloned 
into pMW172 vector using ¶1GH,DQG¶(FR5,UHVWULFWLRQVLWHVDQGDQLQWHUQDO+LQG,,,UHVWULFWLRQ
site linker. RGECO and RGECO-TnT were similarly sub-cloned into pMW172. Proteins were 
expressed in BL21-DE3(pLysS) E.coli induced using 0.4mmol/L ,VRSURS\Oȕ-D-1-
thiogalactopyranoside for 4 hours. Bacterial pellets recovered by centrifugation (10,000xg for 10mins) 
were lysed in buffer containing 25mmol/L Tris-HCl, pH 7.5, 20% sucrose, 1mmol/L EDTA, 
200mmol/L NaCl,5 mol/L urea, 0.1% Triton X-100. All proteins were purified using an AKTA-
UPC900 FPLC using HiTrap FF chromatography columns (GE Healthcare, Amersham). GFP-TnT 
and TnT-GFP were purified using sequential cation (in buffer containing 6mol/L urea, 1mmol/L 
EDTA, 1mmol/L 2-mercaptoethanol, 20mmol/L MOPS, pH 6.0) followed by anion (in buffer 
containing 6mol/L urea, 1mmol/L EDTA, 1mmol/L 2-mercaptoethanol 50mmol/L Tris-HCl pH 8.0) 
exchange chromatography. GFP-TnC and TnC-GFP were purified by anion (pH 8.5) exchange 
chromatography. GFP-TnI and TnI-GFP were purified by sequential cation and anion exchange 
chromatography. RGECO and RGECO-TnT were purified using sequential anion (pH 8.0) exchange 
chromatography, ammonium sulphate fractionation (to 50% for RGECO and 35% for RGECO-TnT) 
and finally Hydrophobic Interaction Chromatography (HIC) (in buffer containing 30% ammonium 
sulphate, 200mmol/L NaCl2 1mmol/L ditiothretol and 30mmol/L 4-(2-hydroxyethyl)-1-
piperazineethanesulphonic acid (HEPES)). Ion exchange columns were eluted using a 0-2mol/L NaCl 
gradient, the HIC column was eluted with a 30±0% ammonium sulphate gradient. 6-Histidine-tagged 
RGECO-TnI was cloned into a PET23a vector and expressed as above, and purified using a HisTrap 
HP column (GE Healthcare) in a buffer containing 15.48mmol/L Na2HPO4, 4.52mmol/L NaH2PO4, 
500mmol/L NaCl, and 6mol/L Urea (Histag buffer), followed by washing in Histag buffer with 
20mmol/L Imidazole (pH 7.0), then eluted in an increasing Histag buffer gradient containing 
500mmol/L Imidazole (pH 7.0). Eluted fractions were assessed for purity using 12% SDS-PAGE gels, 
stained with Coomassie brilliant blue. Histag was cleaved using a thrombin kit (Merck) following the 
manufactures instructions. Wild type human recombinant TnT, TnI, TnC and Ala-Ser-Į-TM39 were 
purified as previously described38. Troponin complex containing either WT, GFP-TnT, TnT-GFP, 
GFP-TnC, TnC-GFP, GFP-TnI, or TnI-GFP were reconstituted by dialysis into buffer containing 
10mmol/L imidazole pH 7.0, 1mmol/L DTT, 0.01% azide, 0.1mol/L CaCl2, 6mol/L urea and 1mol/L 
KCl. Urea was reduced stepwise from to 2 then 0mol/L, then KCl was reduced stepwise from 1mol/L 
to 800 ± 600 ± 400 ± 200mmol/L KCl in a series of 3 hour dialyses. Tn Complex was purified using 
size exclusion chromatography in 200mmol/L KCl dialysis buffer. Purity was analysed by SDS-
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PAGE. Purified troponin complexes were dialysed into buffer containing 5mmol/L 1,4-
Piperazinediethanesulphate pH 7.0, 3.87mmol/L MgCl2, 1mmol/L DTT for ATPase assay 
experiments. Actin and myosin-S1 was extracted from rabbit skeletal muscle as described39, 40. 
In vitro acto-myosin ATPase assays 
ATPase assays were carried out as described8, 38. BULHIO\DPDVWHUVWRFNRIȝPRO/DFWLQ
ȝPRO/P\RVLQ6ȝPRO/$OD-Ser-Į-70DQGȝPRO/ Tn complex were mixed in buffer 
containing 5mmol/L 1,4-Piperazinediethanesulphate pH 7.0, 3.87mmol/L MgCl2, and 1mmol/L DTT. 
To ensure precise thin filament protein stoichiometry, each stock was centrifuged at 384000xg for 15 
minutes. Recovered pellets were aliquoted and set to a range of [Ca2+]free from pCa 4.5-8.5 using 
Maxchelatior (http://maxchelator.stanford.edu/CaEGTA-TS.htm). ATPase reactions were initiated by 
addition of 3mmol/L ATP and incubated at 37°C for 15 minutes. Each reaction was quenched in 5% 
TCA, finally 1% ammonium molybdate in 0.5mol/L H2SO4, followed by 40% iron(II)sulphate in 
0.5mol/L H2SO4 was used to measure inorganic phosphate. Absorbance (A700) measurements were 
converted to absolute activity (sec-1). Calcium-sensitivity data was fitted to the Hill equation using 
KaleidaGraph (Synergy Software).  
Hill equation:       ൌ ୅ౣ౟౤ାሺ୅ౣ౗౮ି୅ౣ౟౤ሻଵାଵ଴ሺሺ౦ి౗ష౦ి౗ఱబሻൈ೙ౄሻሻ 
Where:  A=ATPase rate; Amin=Minimum ATPase rate; Amax=Maximum ATPase rate; pCa=-log 
[Ca2+]; pCa50=- log [Ca2+] required for half maximum ATPase activity; nH=Hill coefficient. 
Calcium binding Kd calculations 
For steady state Ca2+ binding affinity (Kd) for RGECO, RGECO-TnI and RGECO-TnT, 
ȝmol/L of protein was dialysed into buffer containing 130mmol/L NaCl, 10mmol/L 4-(2-
hydroxyethyl)-1- piperazineethanesulphonic acid (HEPES), 1mmol/L dithiothretol, 1.3mmol/L 
MgCl2, pH 7.3. A range of free[Ca2+] conditions were set between 3.16nmol/L (pCa 8.5) and 
ȝmol/L (pCa 4.5) using 1mmol/L EGTA and the corresponding concentration of CaCl2. Steady 
state fluorescence readings were made in an Ultraclear bottom 96-well microplate using a FLUOstar 
Omega plate reader (BMG LABTEC,  Germany), using 544nm excitation and 590/10nm emission 
filters at both 25 and 37°C. Fluorescence emission intensities were plotted vs free[Ca2+] and fitted to 
the Hill equation to calculate Kd values for each protein and condition. For Ca2+ displacement (koff), 
125nmol/L RGECO-TnT plus 5µmol/L CaCl2 was mixed with 5mmol/L EGTA in a buffer containing 
130mmol/L NaCl, 10mmol/L 4-(2- hydroxyethyl)-1-piperazineethanesulphonic acid (HEPES) 
1.3mmol/L MgCl2, 1mmol/L dithiothretol, pH 7.3 with NaOH. RGECO or RGECO-TnT was loaded 
into a Stopped-flow system (HiTech Scientific, Bradford-on-Avon, UK), concentrations after mixing 
1:1 in the stopped-flow. Fluorescence was excited at 546nm (100W Xe/Hg lamp and monochromator) 
and emission monitored through an OG-590 glass filter. Data was fitted to a single exponential 
decrease in fluorescence of 50-100%, depending upon temperature. For calcium binding (kon), 
125nmol/L RGECO-TnT was measured at 10µmol/L free calcium by mixing with a buffer containing 
2.125mmol/L Ca. EGTA and 0.2mmol/L EGTA with the same filter set as before. Fluorescence 
increase upon Ca2+ addition was fitted to a single exponential. The observed single exponential rate 
constant, kobs, was extracted for kon and koff for both sensors, at a range of temperatures between 25 
and 37°C. To estimate the dissociation constant, we using the equations Kd = kobs-off [Ca]/ kobs on; 
these were comparable to steady state Kd values. 
Determination of Quantum Yield and Molar Extinction Co-efficient  
Quantum yield and molar extinction co-efficient was determined for each Ca2+ sensor 
following41. Quantum yield standards were mCherry (for RGECO) and RGECO for RGECO-TnT. 
The concentration of protein in buffer containing 10 mM HEPES, 1.3mmol/L MgCl2 and 1mmol/L 
dithiothreitol was determined using BCA assay (Pierce) and set to either pCa 4.5 of 8.5.The protein 
concentration was reduced to an absorbance at the excitation wavelength between 0.2 and 0.6. 
DLOXWLRQVWRDEVRUEDQFH¶VRI0.03 and 0.04 were made for each protein solution and 
standard. The fluorescence emission spectra at Ex F568 were recorded using an RF-1501 
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spectrofluorimeter (Shimadzu, Japan). Total fluorescence intensities were obtained by integration. 
Integrated fluorescence intensity vs. absorbance was plotted for each protein and each standard. 
4XDQWXP\LHOGVZHUHGHWHUPLQHGIURPWKHVORSHV6RIHDFKOLQHXVLQJWKHHTXDWLRQĭSURWHLQ 
ĭVWDQGDUGî6SURWHLQ6VWDQGDUG([WLQFWLRQFRHIILFLHQWVZHUHGHWHUPLQHGfrom the absorption 
spectrum of both RGECO and RGECO-TnT at pCa 8.5 and 4.5 in the buffer above using a plate 
reader (BMG LABTECH, Germany). Peak Absorbance wavelengths were determined to be A465 in 
low Ca2+ and A581 in high Ca2+. Absorbance measurements were converted to 1 cm path length using 
BMG Omega software. Extinction coefficients were calculated by dividing the peak absorbance 
maximum by protein concentration. 
Immunofluorescence 
GPCMs were fixed in 4% paraformaldehyde, washed in PBS, permeabilized and blocked in 
0.1% Triton X-100, 3% BSA in PBS. Primary antibodies (1:500 anti-alpha actinin (Sigma, clone EA-
53, A7811), 1:200 anti-DsRed (Clontech, 632496), 1:8 anti-Flagtag (Sigma, F1804)) were added 
overnight at 4°C, washed in PBS, and secondary antibodies added (goat anti-rabbit IgG Alexa 568 
(1:200) (Invitrogen, A21069) and goat anti-mouse IgG Alexa 633 (1:200) (Invitrogen, A21053)) for 1 
hour at room temperature, washed in PBS and mounted on slides in ProLong Diamond antifade with 
DAPI (ThermoFisher). Slides were imaged on a Leica TCS SP5 confocal microscope with a 63x oil 
immersion lens, images data was extracted with Leica LAS and ImageJ (NIH, USA). Control slides 
were prepared excluding the primary antibody for all IF experiments, negligible background 
fluorescence was detected in all cases.   
Subcellular fractionation and western blotting  
GPCMs were fractionated to recover cytoplasmic and sarcomeric/cytoskeletal samples 
following42. 300,000 cardiomyocytes were centrifuged, re-suspended in buffer containing, 20mmol/L 
Tris-HCl pH 7.4, 2mmol/L EDTA, 0.5mmol/L EGTA, 0.3mmol/L sucrose and homogenised for 1 
minute. Cells were pelleted at 1000xg for 5mins, the supernatant/cytoplasmic fraction was retained for 
SDS-PAGE analysis and western blotting. The cell pellet was washed 3 times in fractionation buffer + 
1% Triton X-100 each time pelleting the sarcomeric fraction by centrifugation at 1000xg for 5mins. 
Finally, the sarcomeric fraction was re-suspended in fractionation buffer (without Triton X-100) and 
prepared for western blotting. Subcellular fractions and GPCM lysates were run on a 12% 
polyacrylamide gel, transferred onto PVDF membrane, and blocked with 5% bovine milk in Tris 
buffered saline, 0.1% Tween-20 (TBS-T) for 1hour. Primary antibodies were incubated overnight at 
4°C in 5% bovine milk in TBS-T (1:2000 anti-cTnT (Sigma, SAB2108239), 1:4000 anti-ERK (Cell 
Signaling Technologies, 4695s), 1:5000 anti-FLAG-tag (Sigma, F3165), 1:10000 anti-GAPDH 
(Millipore, ABS16), 1:2000 anti-TnI (TNNI3, Aviva Systems Biology, ARP41391_P050). 
Membranes washed in TBS-T were incubated in secondary antibodies (1:10000 anti-rabbit HRP (GE 
Healthcare, NA934), 1:10000 anti-mouse HRP (GE Healthcare, NA931)) for 1 hour at room 
temperature, washed in TBS-T then developed with ECL select (GE Healthcare) and imaged on a 
ChemiDoc MP (BioRad). Densitometric measurements to compare single verses double infected 
levels of FLAG-tag protein were carried out using Image Lab software (BioRad), and normalised to 
GAPDH loading controls for each comparison.   
Sarcomere length measurements 
Sarcomere length measurements were performed using IonOptix µstep apparatus and the 
manufacturerV¶VWDQGDUGRSHUDWLQJLQVWUXFWLRQV&HOOV, electrically paced at 40 volts, 0.5 Hz, 37°C 
were perfused with buffer containing 150mmol/L NaCl, 10mmol/L HEPES, 7mmol/L glucose, 
1mmol/L MgCl2, 1mmol/L KCl, 0.3mmol/L NaH2PO3, 1.8mmol/L CaCl2, at pH 7.4. Cells displaying 
asynchronous contractility, excessive blebbing/dysmorphology were ignored for acquisition. Similarly 
cells with contractile magnitudes or velocities exceeding 2 standard deviations from the mean upon 
analysis were also excluded due to phenotypic heterogeneity arising in cultured primary cells. 
Imaging and analysis 
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GPCMs imaged on an Olympus IX81 inverted microscope (Olympus, Japan) with a C-1900 
EMCCD camera (Hamamatsu, Japan) were electrically paced at 0.5Hz in a humidified chamber at 
37°C. Videos (28seconds, 25fps) were acquired through an Olympus UPlanFLN 10x lens (NA 0.3) 
with the RFP filter set of 560/25 nm (excitation), 620/60 nm (emission) with a 565 nm dichroic mirror 
using CellR software (Olympus) as previously described43. RGECO, RGECO-TnI and RGECO-TnT 
adenovirally transduced GPCMs were incubated with 250nmol/L MYK-461, 200µmol/L omecamtiv 
mecarbil or 10µmol/L levosimendan 20mins before imaging. For Fluo-4 comparison, RGECO-TnT 
transduced cardiomyocytes were loaded with 1ʅmol/L Fluo-DVSHUWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV
for 5minutes and imaged using RFP and GFP (485/20-25 nm (excitation), 525/50 nm (emission) 
with a 495 nm dichroic mirror) filter sets. 
  
Raw image data was extracted using CellR (Olympus), and analysed in Excel (Microsoft). 
From a single cell, 10 transients were extracted and averaged to give a single transient in a 2 second 
interval per cell. Time to 50% contraction, time to 50% baseline (from peak), time of peak, or time 
above 50% was determined. Peak intensity analysis was performed as previously described for 
intensiometric sensors44, 45  οܨܨ ൌ ܨሺݐሻ െ ܨሺ݉݅݊ሻܨሺ݉݅݊ሻ ൈ ͳͲͲ 
Where F(t) is the fluorescence intensity at time (t), and F(min) the minimum fluorescence intensity 
during the averaged transient. 
Statistics 
 For all single cells experiments, comparisons were from at least three separate cell isolations, 
where approximately equal numbers of cells (±5) were taken from each preparation on an experiment-
to-experiment basis. Data was firstly tested for normality '¶$JRVWLQR-Pearson). Sarcomere length 
measurements were made using unpaired Students t-test. Wilcoxon T-test was used for the 
comparison of Fluo-4 to RGECO-TnT. RGECO to RGECO-TnT/TnI and pacing frequencies were 
compared using non-parametric Kruskal-Wallis one-way ANOVA. Drugs and WT to mutant troponin 
were compared using non-parametric Mann-Whitney test (Graphpad Prism). Once acquired, all data 
was blinded prior to extraction and analysis.  
Results 
Development and In vitro characterisation of myofilament RGECO Ca2+ sensors 
To develop a myofilament-restricted GECI, fusion proteins of green fluorescent protein 
(GFP) at the N- and C-terminus of each troponin subunit were screened to identify sites preserving in 
vitro acto-myosin ATPase Ca2+ dependent regulation. GFP conjugation to the N-terminus of either 
TnT or TnI maintained Ca2+ regulation (Figure 1, Online Table I). Subsequently, the red GECI 
RGECO41 was conjugated to the N-terminus of troponin-T and troponin-I (Online Figure X, XI). In 
vitro characterisation of the calcium indicator properties of RGECO-TnT and RGECO-TnI showed Kd 
of 764.5±17.6nmol/L, and 657.3±27.3nmol/L respectively under physiological pH46, temperature and 
magnesium concentration47 (Online Figure I), with preservation of dynamic range and 
excitation/emission spectra (Figure 2A-C, Online Table II). This is compatible with previous reports41 
(RGECO Kd = 484nmol/L at 25°C and 3mmol/L MgCl2). At physiological temperature, Ca2+ on (kobs 
ȝmol/L-1s-1 DWȝmol/L free Ca2+) and off (koff = 16.9s-1) rates for myofilament RGECO were 
approximately twice those observed at 25ºC (Online Figure II). Importantly in intact, but unloaded, 
GPCMs the presence of RGECO-TnT/TnI did not affect sarcomere shortening compared to 
uninfected controls (Figure 2D and E, Online Figure III). 
Characterisation of RGECO-TnT and RGECO-TnI Ca2+ sensors in cardiomyocytes 
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RGECO-TnT or RGECO-TnI localize to the sarcomere, without Z-disk accumulation, 
following adenoviral transduction of GPCMs. Conversely, unconjugated RGECO is broadly 
distributed with weak Z-disk accumulation (Figure 3A, Online Figure IV). 48 hours following viral 
infection, total TnI contained 58.7±11.0% (n=5) RGECO-TnI and similarly TnT contained 54.3±5.5% 
(n=4) RGECO-TnT (Figure 3B and C). RGECO-TnI and RGECO-TnT both show cyclical 
fluorescence in paced cardiomyocytes (Figure 3D and E), with equivalent kinetics in untreated 
GPCMs stimulated at 0.5Hz (Figure 3F, Online table III). The on and off rates of fluorescence differ 
in both myofilament localised indicators compared to the unrestricted RGECO. On rates were 
significantly VORZHUǻ750 on = 47±5 and 39±4msec for RGECO-TnT and RGECO-TnI respectively), 
whilst off rates were significantly IDVWHUǻ750 off = -26±8 and -41±11msec for RGECO-TnT and 
RGECO-TnI respectively) than unrestricted RGECO (Online Table III). Interestingly, these rate 
differences are qualitatively preserved when RGECO-TnT emissions are compared to the chemical 
dye Fluo-4 (Online Figure V).  
To explore the sensitivity of RGECO-TnI/RGECO-TnT to detect changes in Ca2+ transient 
duration or magnitude that might be provoked by small molecules or disease causing mutations we 
performed a series of experiments with well annotated modifiers of cardiac physiology. To ensure 
changes in Ca2+ kinetics can be observed we used the reverse-rate dependence phenomenon that 
accompanies increasing frequency of electrical stimulation. All genetically encoded probes respond to 
increased pacing frequencies (0.5, 1 and 2 Hz) with increased speed of binding and release as the Ca2+ 
transient duration shortens (Online Figure VI). Since the lowest pacing frequency produces the 
longest Ca2+ transient, and maximizes experimental duration, we performed subsequent experiments at 
0.5 Hz.  
Small molecule effects on cytoplasmic and myofilament Ca2+ dynamics 
To investigate the ability of RGECO-TnI/RGECO-TnT to detect localized changes in Ca2+ 
compared to an unrestricted sensor we used three small molecule modulators of myofilament 
contractility. MYK-461 was selected as a myosin ATPase inhibitor (Figure 4). Omecamtiv mecarbil, 
which increases the interaction between actin and myosin independently of Ca2+ was selected as a 
myosin activator (Figure 5), and finally, the inodilator levosimendan which stabilizes the Ca2+ bound 
form of TnC activating the myofilament (Figure 6). In agreement with previous observations48 
omecamtiv mecarbil did not change any aspect of the Ca2+ transient with any probe (Figure 5). By 
contrast, peak amplitudes increase in the presence of levosimendan, and reduce in the presence of 
MYK-461. The myofilament restricted indicators report greater changes in peak amplitude ratio 
compared to the unrestricted control. The relative reductions in fluorescence conferred by MYK-461 
were -9.5±3.8 %, -21.4±4.3% and -42.7±4.1% for RGECO, RGECO-TnT and RGECO-TnI 
respectively. Analogous increases in fluorescent amplitude following levosimendan treatment were 
+47.5±6.6%, +198.8±23.8% and +170.8±16.5% for RGECO, RGECO-TnT and RGECO-TnI 
respectively. Additionally, the myofilament localised RGECO reveals changes to the rate of Ca2+ 
binding and release in the presence of both MYK-461 and levosimendan contrasting with the results 
obtained with the cytoplasmic probe (Figure 4 and 6). Both myofilament restricted indicators in 
response to 250 nM MYK-461 and 10 ȝ0OHYRVLPHQGDQ reduce the T50On times (RGECO-TnT -
0.031±0.002 sec, -0.008±0.002 sec; RGECO-TnI -0.019±0.004 sec to -0.018±0.002 sec for MYK-461 
and levosimendan respectively) whilst RGECO detects no change. Interestingly the unrestricted 
RGECO reports greater changes to T50Off compared to the restricted sensors (Figure 4, and 6), which 
might reflect hierarchical Ca2+ reuptake. Importantly, neither compound affects the intrinsic Ca2+ 
sensor function of RGECO-TnT (Online Figure VII).  
Cytoplasmic and myofilament localised Ca2+ dynamics in HCM 
Small molecule action in intact cells may include both on- and off-target components. 
Therefore, we explored whether the targeted RGECO strategy identified alterations in the calcium 
transient driven by HCM causing mutations, which should principally work through the myofilament. 
Specifically, previous contractility data suggests that peak amplitude should increase, and also phase 
shift by ~100 msec, however these have been undetectable with fura-28. Recombinant adenovirus 
expressing RGECO-TnT was used to study the effects of wild type (WT) cTnI or cTnI R145G 
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expression; conversely, adenovirus expressing RGECO-TnI was used to observe the effects of WT 
cTnT or cTnT R92Q in GPCMs. The mutually exclusive expression of HCM mutant protein and 
sensor conjugate allows changes in Ca2+ flux to be attributed to the mutation independently of the 
consequence of the mutation itself. 
  Previously we showed a mutant transgene expression approach models autosomal dominant 
human HCM (~54% for cTnT R92Q and ~49% for cTnI R14510) and produces hypercontractility as a 
cellular manifestation of disease phenotype. Here, as we co-transduced separate adenoviruses 
containing the disease gene and the complementary Ca2+ indicator, adjustments to expression levels of 
singly verses doubly transduced cells required optimization of the multiplicities of infection (MOI), 
with subsequent western blot analysis to ensure doubly transduced cells had equivalent FLAG-tagged 
protein expression to singly transduced cells10 (Online Figure VIII). Immunolocalization experiments 
using DsRed and FLAG-tag antibodies to detect RGECO and HCM mutant troponin show no 
alterations to protein localization or sarcomeric structure as previously described10 (Online Figure IX)     
At the myofilament, compared to the WT control, both cTnT R92Q and cTnI R145G exert 
similar effects. The peak amplitude is delayed and elevated combined with slower T50 release times 
indicative of HCM causing thin filament mutations promoting more Ca2+ at the myofilament for 
longer intervals. Conversely, the whole cell indicator reports differential changes in peak systolic Ca2+ 
only for cTnI R145G, and no change in systolic Ca2+ for cTnT R92Q (Figure 7A-E, Online Table IV). 
The delay in time of peak Ca2+ correlates with previously published sarcomere length traces showing 
a delayed peak contraction time, which are overlooked by chemical dyes10. All indicator combinations 
detected increased time to 50% binding in both cTnT R92Q and cTnI R145G (Figure 7F, Online 
Table IV) and T50 release predicted (Online Table IV) from previous work measuring whole cell Ca2+ 
dynamics10. 
 
Discussion 
Here we show that a genetically encoded  Ca2+ sensor, RGECO, can be targeted to the 
myofilament without perturbing contractility, or indicator function. This allows direct Ca2+ 
measurement in a key compartment of the cardiomyocyte historically studied indirectly. The 
availability of two targeted sensors, which are almost functionally equivalent, should facilitate studies 
of calcium handling at the myofilament in response to drugs or disease causing mutation.  
GECIs applied to GPCMs reveal findings that contrast with calcium dyes. For example 
GECIs show the myosin ATPase inhibitor MYK-461 alters Ca2+ binding, release and signal 
amplitude, none of which were previously described in chemical dye studies30. Furthermore, 
myofilament targeting enhances the observed effect size when cardiomyocytes are treated with 
levosimendan. The mechanism of levosimendan action is debated, with a direct Ca2+ sensitizing effect 
meditated through TnC, a cAMP mediated effect through phosphodiesterase III inhibition49, and 
mitochondrial potassium channel activation50 all reported. While our data do not define the relative 
contributions, or the intermediates in the mode of action, they do show potent elevation of 
myofilament Ca2+ is combined with an increase in total cell Ca2+. The whole cell consequences are 
undesirable, and possibly attributable to off-target effects, as the R92Q-TnT mutant demonstrates that 
increased myofilament Ca2+ need not translate into increased whole cell Ca2+. Similarly, omecamtiv 
mecarbil48 alters contraction but does not change Ca2+ at the whole cell, or myofilament level in this 
model. 
The myofilament restricted Ca2+ indicators reveal both cTnT R92Q and cTnI R145G HCM 
causing variants increase myofilament peak Ca2+ and delay release. Therefore the increased 
myofilament Ca2+ affinity common to both mutations8 directly correlates with increased microdomain 
[Ca2+]. This is compatible with previous work showing the same mutations increased myofilament 
Ca2+ buffering and altered [Ca2+]  inferred by a rise in diastolic fura2 fluorescence10. The RGECO-
TnI/TnT data contrast with results from the unrestricted RGECO indicator; where systolic peak 
intensity differences are observed only for cTnI R145G (a large increase) but not cTnT R92Q 
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suggesting distinct consequences of these mutations. Since prior work excluded other factors such as 
fractional Ca2+ release from the SR10, the differences appear determined by what happens at the 
myofilament. This is mechanistically plausible as the cTnI R145G mutation directly increases Ca2+ 
binding to the regulatory site (I) of cTnC, whereas cTnT R92Q is structurally distant from the Ca2+ 
binding sites in the troponin complex and sensitizes myofilament Ca2+ binding via alterations to co-
operative communication8. Furthermore previous studies show the cTnI R145G mutation has a greater 
effect on Ca2+ buffering than TnT R92Q (7Q754ǻ.d=582nmol/L, 7Q,5*ǻ.d=1082nmol/L 
compared to WT)10. We believe greater severity of the R145G mutation, which has a more 
pronounced contractility effect8, underpins the differential observations of changes to bulk Ca2+ with 
RGECO between the two mutants although exactly what makes the R145G cTnI mutation more 
severe is unknown. Interestingly a CRISPR engineered thick filament HCM iPS-CM model (MYH7 
R453C) has raised peak systolic Ca2+ visualized by unrestricted RGECO51. From this we postulate 
that cytoplasmic Ca2+ increases could be a hallmark of some HCM causing mutations. This raises an 
important, potentially clinically significant, concept. HCM represents a common clinical end-point of 
many different mutations. There is an unmet need to understand the shared and distinct consequences 
of individual mutations. Common mechanisms central to disease pathogenesis may be preferable as 
therapeutic targets, but they may leave residual aspects of individual mutations untreated. The impact 
of this is currently uncertain, but we may gain insight in to this through trials such as EXPLORER 
investigating MYK-461 in HCM cohorts.  
Ca2+ overload specifically at the myofilament is thought to activate hypertrophic signalling 
pathways as a component of the HCM disease mechanism13, 52, 53, however measuring this directly in 
living cells has remained elusive. This is the first study to not only show this occurs, but also that the 
phase shift in contractility is paralleled by a shift in the Ca2+ transient using any of the three protein 
indicators tested. These indicators simplify, and accelerate the process of studying Ca2+ dynamics at 
the myofilament without the need for multiple inferred observations of total and free Ca2+ using 
simultaneous patch clamping and chemical Ca2+ dyes10, 11, 20. Although the proteins used to detect Ca2+ 
are physically bulky and may have unmeasured effects on the intricate structure of the myofilament, 
or myofilament Ca2+ buffering capacity, contractile impairment is not seen in the GPCM transient 
expression model; this contrasts with the chemical dyes typically used to study Ca2+10, 54. A limitation 
of the RGECO indicators is their intensiometric nature, which precludes robust calibration allowing 
an observed signal to be converted to [Ca2+].  However, GECIs reveal changes in Ca2+ amplitude and 
kinetics that are overlooked with dye based probes. This opens a new investigative pathway in 
understanding this important microdomain within contractile cells which should be generally 
applicable to conditions affecting cardiac contractility and Ca2+ handling. They improve the fidelity of 
screening tools for small molecule evaluation in the heart. 
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Figure 1. The effect of GFP conjugation to the N and C terminus of troponin subunits on 
myofilament function. Myofilament function was assessed using in vitro actin activated acto-myosin 
S1 ATPase assays. Control (unconjugated) troponin complexes (grey lines) were compared pairwise 
to troponin complex reconstituted with subunits conjugated to the N or the C terminus of GFP as 
illustrated (red lines). n=3-5 error bars are ± SEM.  
 
Figure 2. Fluorescent and contractile properties of RGECO, RGECO-TnT and RGECO-TnI. 
Steady state fluorescence excitation, emission spectra (peak excitation (Ex) = 564nm) / peak emission 
(Em) = 581nm) were obtained at pCa4.5 and subtracted from paired spectra at pCa8.5 for purified 
recombinant RGECO (A), RGECO-TnT (B) and RGECO-TnI (C). Sarcomere shortening during 
electrical pacing (0.5Hz) of isolated adult cardiomyocytes was used to test cardiac contractile function 
in non-transduced and either RGECO, RGECO-TnT or RGECO-TnI transduced GPCMs by 
measurement of the sarcomeric length during contraction (n=33-52) (D) or by fractional shortening 
(E). 
 
Figure 3. Characterisation of RGECO, RGECO-TnT and RGECO-TnI in GPCMs. Adenovirally 
expressed RGECO-TnT and RGECO-TnI (red in the merged images) localises to the I band in 
confocal microscopy of GPCMs, whilst RGECO shows diffuse staining (n=4) (A); Z-disks are 
UHYHDOHGE\Į-DFWLQLQVWDLQLQJJUHHQLQWKHPHUJHGLPDJHV6FDOHEDU ȝP,QWHQVLW\SURILOHSORWV
VSDQQLQJWZRVDUFRPHUHVĮ-actinin (green line) labels the z-disc, DsRed (red) labels the Ca2+ sensors. 
Western blot analysis of GPCMs transduced with RGECO-TnT (B) or RGECO-TnI (C) indicates that 
54.3±5.5% (n=5)/58.7±11.0% (n=4), respectively, of Troponin is composed of RGECO conjugated 
Troponin. Raw Ca2+ transients of paced GPCMs transduced with RGECO-TnT (D) or RGECO-TnI 
(E). Averaged Ca2+ transients of 0.5Hz paced GPCMs transduced with RGECO, RGECO-TnT or 
RGECO-TnI (F) was used to compare Ca2+ transients between cytoplasmic RGECO and myofilament 
specific RGECO-TnT and RGECO-TnI. 
 
Figure 4. The effects of MYK-461 on Ca2+ transient measurements in GPCMs with RGECO, 
RGECO-TnT or RGECO-TnI. Averaged Ca2+ transients of 0.5 Hz paced GPCMs transduced with 
RGECO, RGECO-TnT or RGECO-TnI was used to compare the effects of 250nmol/L MYK-461 (A). 
Each comparison is made in paired experiments between drug treated (solid lines) and DMSO control 
treated (dashed lines) for RGECO infected (red), RGECO-TnT infected (purple) and RGECO-TnI 
infected (blue) cells. Dot plots for all extracted parameters are plotted in (B) (n=43-82 cells from n=3 
isolations). Lines are median average and error bars are interquartile range,  **= p<0.01 and  ***= 
p<0.001 using an unpaired Mann-Whitney test comparing untreated to treated cells.  
 
Figure 5. The effects of omecamtiv mecarbil on Ca2+ transient measurements in GPCMs with 
RGECO, RGECO-TnT or RGECO-TnI. Averaged Ca2+ transients of 0.5Hz paced GPCMs 
transduced with RGECO, RGECO-TnT or RGECO-TnI was used to compare the effects 200nmol/L 
omecamtiv mecarbil (A). Each comparison is made in paired experiments between drug treated (solid 
lines) and DMSO control treated (dashed lines) for RGECO infected (red), RGECO-TnT infected 
(purple) and RGECO-TnI infected (blue) cells Dot plots for all extracted parameters are plotted in (B) 
(n=42-75 cells from n=3 isolations). Lines are median average and error bars are interquartile range, 
all groups were not significant using an unpaired Mann-Whitney test comparing untreated to treated 
cells.  
 
Figure 6. The effects of levosimendan on Ca2+ transient measurements in GPCMs with RGECO, 
RGECO-TnT or RGECO-TnI. Averaged Ca2+ transients of 0.5Hz paced GPCMs transduced with 
RGECO, RGECO-TnT or RGECO-TnI was used to compare the effects 10ʅmol/L levosimendan (A). 
Each comparison is made in paired experiments between drug treated (solid lines) and DMSO control 
treated (dashed lines) for RGECO infected (red), RGECO-TnT infected (purple) and RGECO-TnI 
17 
 
infected (blue) cells. Dot plots for all extracted parameters are plotted in (B)  (n=71-83 cells from n=3 
isolations). Lines are median average and error bars are interquartile range, *=p<0.05 **= p<0.01 and  
***= p<0.001 using an unpaired Mann-Whitney test comparing untreated to treated cells.  
 
Figure 7. Cytoplasmic and myofilament localised Ca2+ transients with adenovirally transduced 
cTnT R92Q and cTnI R145G. Averaged Ca2+ transients of 0.5Hz paced GPCMs transduced with 
RGECO (A and B) or RGECO-TnI/RGECO-TnT (C and D) was used to compare Ca2+ transient 
effects between GPCMs transduced with either WT cTnT/cTnT R92Q (A and C), or WT cTnI/cTnI 
R145G (B and D). Peak amplitude ratio (EDQGǻYDOXHVIRUWLPHWRELQGLQJ2QF) and 50% 
release (Off) (G) are plotted including significance and labelled cytoplasmic (c) and myofilament (m) 
(n=94-124 cells from n=3 isolations). Error bars are SD, **= p<0.01 and  ***= p<0.001 using a 
Mann-Whitney test comparing WT troponin to mutant troponin transduced cells.  
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Novelty and Significance 
What is known? 
Ɣ Hypertrophic cardiomyopathy (HCM) mutations and small molecule modulators of contractility 
alter how the cardiomyocyte handles calcium.  
Ɣ Historical methods to measure calcium at the myofilament are indirect because the chemical 
calcium dyes commonly used to visualise calcium are not possible to confine to subcellular regions.   
Ɣ An additional limitation of using chemical calcium dyes in this context is their reported attenuation 
of contractility. 
What new information does this article contribute?    
Ɣ Calcium sensitive proteins, here we use RGECO, can be fused to two components of the thin 
filament (troponin I and troponin T) without adversely affecting the indicator, or native protein 
function, allowing calcium measurement from the sarcomere directly.  
Ɣ We find that in spite of their size and calcium binding, amino terminal fusions are well tolerated and 
do not alter contractility biochemically or in intact cells.  
Ɣ GECIs localised to the sarcomere detect changes to calcium amplitude or kinetics conferred by 
small molecules and HCM mutations that were not seen by traditional chemical calcium dyes or 
unrestricted GECIs that distribute throughout the cell. 
We apply the virally delivered genetically encoded calcium indicators RGECO to measure beat-to-
beat calcium transients in cardiomyocytes. By direct fusion to troponin I or troponin T, we have 
localised RGECO to measure calcium cycling within the contractile apparatus, where calcium is the 
master regulator of force production. Small molecule regulators of contractility (MYK-461, 
omecamtiv mecarbil and levosimendan) exert subtle changes to calcium at the myofilament which are 
more easily detected by these indicators working without the background noise coming from the 
whole cell. We find these tools increase our understanding of the mechanism by which HCM causing 
mutations alter microdomain calcium handling to drive disease state remodelling. Importantly the 
kinetic changes in contractility that arise in response to disease causing mutation are now mirrored by 
protein based calcium indicators. Overall, our work has developed novel tools to study myofilament 
domain calcium directly without several of the limitations encountered in previous strategies. We 
hope this study will inform deeper mechanistic understanding of contractile aspects of cardiovascular 
disease and lead to broader uptake of genetically encoded indicators to study cardiovascular 
physiology.   
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SUPPLEMENTAL MATERIAL
Online Figure I. Ca2+ binding affinity plot of RGECO, RGECO-TnT and RGECO-TnI. The steady state Ca2+
binding affinity of purified recombinant RGECO (red lines) RGECO-TnT (purple lines) and RGECO-TnI (blue lines) 
was assessed by analysis of the fluorescence/pCa relationship at 37 °C, 1.3 mM MgCl2 and pH 7.3 (n=4).
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Online Figure II. Kinetic determination of kon and koff for RGECO-TnT by stopped flow. Arrhenius plots of the 
observed rate constant of Ca2+ binding (A) and Ca2+ release rate constant (B) as determined by stopped flow 
measurement of 0.125 μM purified RGECO-TnT protein. Data for room (25 °C) and body (37 °C) temperature are 
shown in (C).
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Online Figure III. Contractile properties of RGECO, RGECO-TnT and RGECO-TnI. Contractile parameters 
during electrical paced (0.5 Hz) of isolated adult cardiomyocytes transduced and either RGECO, RGECO-TnT or 
RGECO-TnI showing no change in basal sarcomere length (A), time to 50% contraction (B) or time to 50% relaxation 
(C) (n=33-64 cells from n=3 isolations).
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Online Figure IV.  Subcellular fractionation of GPCMs expressing RGECO-TnT and RGECO-TnI. The relative 
subcellular incorporation of RGECO-TnT or RGECO-TnI was assessed by subcellular fractionation of GPCMs 48 
hours after adenoviral infection. Western blots using anti-cTnT or anti-cTnI gave an endogenous band and a conjugate 
band on the sarcomeric fraction (sarc) (A). Re-probing with the predominantly cytoplasmic marker anti-ERK showed 
that subcellular fractionation was of high fidelity (B).    
RGECO-TnT
A
B
RGECO-TnI
Cyto Sarc
RGECO-TnI
Cyto Sarc
TnI
RGECO-TnI
ERK
kDa kDa
kDa kDa
76
52
38
31
76
38
31
23
52
52
38
31
52
38
31
00.2
0.4
0.6
0.8
1
0 0.5 1 1.5 2
Fluo-4
RGECO-TnT
R
e
k
e
a
ti
v
e
 F
lu
o
re
s
c
e
n
c
e
 (
F
/F
0
)
Time Sec
Fluo-4 RGECO-TnT
T50 on (sec) 0.059±0.003 0.088±0.004 *
T50 off (sec) 0.418±0.026 0.316±0.038 *
Online Figure V.  The on and off rates of Ca2+ transients measured with Fluo-4 are significantly different to 
RGECO-TnT in simultaneous measurements if dye and sensor in the same cell. Fluorescence measurements taken 
from cells loaded with 0.5 μmol/L Fluo-4 and expressing RGECO-TnT were measured at 488 nm and 595 nm 
respectively. Emitted transients were from the same cell and therefore enabled direct pairwise comparison of T50 on 
and T50 off rates (n=82 cells from n=3 isolations). Data presented as mean ± SEM, * = p<0.05, using Wilcoxon paired 
t-test.   
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Online Figure VI. RGECO, RGECO-TnT and RGECO-TnI Ca2+ transients show reverse rate dependence in 
times to 50% on and 50% off in response to increased pacing frequency in adult GPCMs. Averaged Ca2+
transients of electrically paced isolated adult cardiomyocytes was used to compare pacing frequencies of 0.5 Hz, 1.0 
Hz and 2 Hz using either RGECO (A), RGECO-TnT (D) or RGECO-TnI (G). Adjacent dot plots show distributions of 
time to 50% binding, and 50% release rates across the pacing range. Shortening of both parameters is apparent for all 
indicators (RGECO (B and C) (n=21 cells from n=2 isolations), RGECO-TnT (E and F) (n=24 cells from n=2 
isolations), and RGECO-TnI (H and I) (n=56 cells from n=3 isolations)). Lines give the median average and error bars 
are ± interquartile range * = p<0.05, ** = p<0.01 and  *** = p<0.001 using one way ANOVA.
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Online Figure VII. MYK-461 and levosimendan had no direct effect on the function of the RGECO-TnT. 
Fluorescence : pCa relationship in the presence of 250 nmol/L MYK-461 and 10 μmol/L levosimendan was used to 
calculate the Kd values tabulated beneath (n=4). Significance values (p) were calculated using one way ANOVA.   
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Online Figure VIII. Effect of dual transduction versus single transduction of adenoviruses on FLAG-tag 
expression. Western blot analysis of GPCMs transduced with WT cTnT, cTnT R92Q, WT cTnI, or cTnI R145G ±
RGECO (A) or RGECO-TnI/RGECO-TnT (B), or uninfected control (UI). Showing no significant effect on FLAG-tag 
expression between dual transduction with the Ca2+ sensor and single transduction without the Ca2+ sensor, n=5.
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Online Figure IX. Effect of dual transduction on the localisation of FLAG-tag expressed protein. 
Immunofluorescence analysis of GPCMs transduced with WT cTnT, cTnT R92Q, WT cTnI, or cTnI R145G ±
RGECO/RGECO-TnI/RGECO-TnT was performed using anti-FLAG tag (green) and anti-DsRed antibodies. No 
significant alterations to the I band localisation of FLAG-tag protein was observed between dual transduction with the 
Ca2+ sensor and previously described single transduction without the Ca2+ sensor.
10 μm
RGECO-TnT DNA sequence
ATGGTAGACTCATCACGTCGTAAGTGGAATAAGGCAGGTCACGCAGTCAGAGCTATAGGTCGGCTGAGCTCACCCGTGGTT
TCCGAGCGGATGTACCCCGAGGACGGCGCCCTCAAGAGCGAGATCAAGAAGGGGCTGAGGCTGAAGGACGGCGGCCACTAC
GCCGCCGAGGTCAAGACCACCTACAAGGCCAAGAAGCCCGTGCAGCTGCCCGGCGCCTACATCGTAGACATCAAGTTGGAC
ATCGTGTCCCACAACGAGGACTACACCATCGTGGAACAGTGCGAACGCGCCGAGGGCCGCCACTCCACCGGCGGCATGGAC
GAGCTATACAAGGGAGGTACAGGCGGGAGTCTGGTGAGCAAGGGCGAGGAGGATAACATGGCCATCATCAAGGAGTTCATG
CGCTTCAAGGTGCACATGGAGGGCTCCGTGAACGGCCACGAGTTCGAGATCGAGGGCGAGGGCGAGGGCCGCCCCTACGAG
GCCTTTCAGACCGCTAAGCTGAAGGTGACCAAGGGTGGCCCCCTGCCCTTCGCCTGGGACATCCTGTCCCCTCAGTTCATG
TACGGCTCCAAGGCCTACATTAAGCACCCAGCCGACATCCCCGACTACTTCAAGCTGTCCTTCCCCGAGGGCTTCAGGTGG
GAGCGCGTGATGAACTTCGAGGACGGCGGCATTATTCACGTTAACCAGGACTCCTCCCTGCAGGACGGCGTATTCATCTAC
AAGGTGAAGCTGCGCGGCACCAACTTCCCCCCCGACGGCCCCGTAATGCAGAAGAAGACCATGGGCTGGGAGGCTACGCGT
GACCAACTGACTGAGGAGCAGATCGCAGAATTTAAAGAGGCTTTCTCCCTATTTGACAAGGACGGGGATGGGACGATAACA
ACCAAGGAGCTGGGGACGGTGATGCGGTCTCTGGGGCAGAACCCCACAGAAGCAGAGCTGCAGGACATGATCAATGAAGTA
GATGCCGACGGTGACGGCACATTCGACTTCCCTGAGTTCCTGACGATGATGGCAAGAAAAATGAATGACACAGACAGTGAA
GAGGAAATTAGAGAAGCGTTCCGCGTGTTTGATAAGGACGGCAATGGCTACATCGGCGCAGCAGAGCTTCGCCACGTGATG
ACAGACCTTGGAGAGAAGTTAACAGATGAGGAGGTTGATGAAATGATCAGGGTAGCAGACATCGATGGGGATGGTCAGGTA
AACTACGAAGAGTTTGTCCAAATGATGACAGCGAAGGGATCCATGTCTGACATAGAAGAGGTGGTGGAAGAGTACGAGGAG
GAGGAGCAGGAAGAAGCAGCTGTTGAAGAGCAGGAGGAGGCAGCGGAAGAGGATGCTGAAGCAGAGGCTGAGACCGAGGAG
ACCAGGGCAGAAGAAGATGAAGAAGAAGAGGAAGCAAAGGAGGCTGAAGATGGCCCAATGGAGGAGTCCAAACCAAAGCCC
AGGTCGTTCATGCCCAACTTGGTGCCTCCCAAGATCCCCGATGGAGAGAGAGTGGACTTTGATGACATCCACCGGAAGCGC
ATGGAGAAGGACCTGAATGAGTTGCAGGCGCTGATTGAGGCTCACTTTGAGAACAGGAAGAAAGAGGAGGAGGAGCTCGTT
TCTCTCAAAGACAGGATCGAGAGACGTCGGGCAGAGCGGGCCGAGCAGCAGCGCATCCGGAATGAGCGGGAGAAGGAGCGG
CAGAACCGCCTGGCTGAAGAGAGGGCTCGACGAGAGGAGGAGGAGAACAGGAGGAAGGCTGAGGATGAGGCCCGGAAGAAG
AAGGCTTTGTCCAACATGATGCATTTTGGGGGTTACATCCAGAAGCAGGCCCAGACAGAGCGGAAAAGTGGGAAGAGGCAG
ACTGAGCGGGAAAAGAAGAAGAAGATTCTGGCTGAGAGGAGGAAGGTGCTGGCCATTGACCACCTGAATGAAGATCAGCTG
AGGGAGAAGGCCAAGGAGCTGTGGCAGAGCATCTATAACTTGGAGGCAGAGAAGTTCGACCTGCAGGAGAAGTTCAAGCAG
CAGAAATATGAGATCAATGTTCTCCGAAACAGGATCAACGATAACCAGAAAGTCTCCAAGACCCGCGGGAAGGCTAAAGTC
ACCGGGCGCTGGAAATAG
RGECO-TnT amino acid sequence
MVDSSRRKWNKAGHAVRAIGRLSSPVVSERMYPEDGALKSEIKKGLRLKDGGHYAAEVKTTYKAKKPVQLPGAYIVDIKLD
IVSHNEDYTIVEQCERAEGRHSTGGMDELYKGGTGGSLVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYE
AFQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYIKHPADIPDYFKLSFPEGFRWERVMNFEDGGIIHVNQDSSLQDGVFIY
KVKLRGTNFPPDGPVMQKKTMGWEATRDQLTEEQIAEFKEAFSLFDKDGDGTITTKELGTVMRSLGQNPTEAELQDMINEV
DADGDGTFDFPEFLTMMARKMNDTDSEEEIREAFRVFDKDGNGYIGAAELRHVMTDLGEKLTDEEVDEMIRVADIDGDGQV
NYEEFVQMMTAKGSMSDIEEVVEEYEEEEQEEAAVEEQEEAAEEDAEAEAETEETRAEEDEEEEEAKEAEDGPMEESKPKP
RSFMPNLVPPKIPDGERVDFDDIHRKRMEKDLNELQALIEAHFENRKKEEEELVSLKDRIERRRAERAEQQRIRNEREKER
QNRLAEERARREEEENRRKAEDEARKKKALSNMMHFGGYIQKQAQTERKSGKRQTEREKKKKILAERRKVLAIDHLNEDQL
REKAKELWQSIYNLEAEKFDLQEKFKQQKYEINVLRNRINDNQKVSKTRGKAKVTGRWK.
Online Figure X. DNA and amino acid sequence of RGECO-TnT. Sequence highlighted red is RGECO, purple is 
human cardiac TnT and black is a BamHI cloning site which corresponds to an additional GS linker sequence in the 
translated amino acid.  
RGECO-TnI DNA sequence
ATGGTAGACTCATCACGTCGTAAGTGGAATAAGGCAGGTCACGCAGTCAGAGCTATAGGTCGGCTGAGCTCACCCGTGGTT
TCCGAGCGGATGTACCCCGAGGACGGCGCCCTCAAGAGCGAGATCAAGAAGGGGCTGAGGCTGAAGGACGGCGGCCACTAC
GCCGCCGAGGTCAAGACCACCTACAAGGCCAAGAAGCCCGTGCAGCTGCCCGGCGCCTACATCGTAGACATCAAGTTGGAC
ATCGTGTCCCACAACGAGGACTACACCATCGTGGAACAGTGCGAACGCGCCGAGGGCCGCCACTCCACCGGCGGCATGGAC
GAGCTATACAAGGGAGGTACAGGCGGGAGTCTGGTGAGCAAGGGCGAGGAGGATAACATGGCCATCATCAAGGAGTTCATG
CGCTTCAAGGTGCACATGGAGGGCTCCGTGAACGGCCACGAGTTCGAGATCGAGGGCGAGGGCGAGGGCCGCCCCTACGAG
GCCTTTCAGACCGCTAAGCTGAAGGTGACCAAGGGTGGCCCCCTGCCCTTCGCCTGGGACATCCTGTCCCCTCAGTTCATG
TACGGCTCCAAGGCCTACATTAAGCACCCAGCCGACATCCCCGACTACTTCAAGCTGTCCTTCCCCGAGGGCTTCAGGTGG
GAGCGCGTGATGAACTTCGAGGACGGCGGCATTATTCACGTTAACCAGGACTCCTCCCTGCAGGACGGCGTATTCATCTAC
AAGGTGAAGCTGCGCGGCACCAACTTCCCCCCCGACGGCCCCGTAATGCAGAAGAAGACCATGGGCTGGGAGGCTACGCGT
GACCAACTGACTGAGGAGCAGATCGCAGAATTTAAAGAGGCTTTCTCCCTATTTGACAAGGACGGGGATGGGACGATAACA
ACCAAGGAGCTGGGGACGGTGATGCGGTCTCTGGGGCAGAACCCCACAGAAGCAGAGCTGCAGGACATGATCAATGAAGTA
GATGCCGACGGTGACGGCACATTCGACTTCCCTGAGTTCCTGACGATGATGGCAAGAAAAATGAATGACACAGACAGTGAA
GAGGAAATTAGAGAAGCGTTCCGCGTGTTTGATAAGGACGGCAATGGCTACATCGGCGCAGCAGAGCTTCGCCACGTGATG
ACAGACCTTGGAGAGAAGTTAACAGATGAGGAGGTTGATGAAATGATCAGGGTAGCAGACATCGATGGGGATGGTCAGGTA
AACTACGAAGAGTTTGTCCAAATGATGACAGCGAAGCTCGAGATGGCGGATGGGAGCAGCGATGCGGCTAGGGAACCTCGC
CCTGCACCAGCCCCAATCAGACGCCGCTCCTCCAACTACCGCGCTTATGCCACGGAGCCGCACGCCAAGAAAAAATCTAAG
ATCTCCGCTTCTAGAAAATTGCAGCTGAAGACTCTGCTGCTGCAGATTGCAAAGCAAGAGCTGGAGCGAGAGGCGGAGGAG
CGGCGCGGAGAGAAGGGGCGCGCTCTGAGCACCCGCTGCCAGCCGCTGGAGTTGACCGGGCTGGGCTTCGCGGAGCTGCAG
GACTTGTGCCGACAGCTCCACGCCCGTGTGGACAAGGTGGATGAAGAGAGATACGACATAGAGGCAAAAGTCACCAAGAAC
ATCACGGAGATTGCAGATCTGACTCAGAAGATCTTTGACCTTCGAGGCAAGTTTAAGCGGCCCACCCTGCGGAGAGTGAGG
ATCTCTGCAGATGCCATGATGCAGGCGCTGCTGGGGGCCCGGGCTAAGGAGTCCCTGGACCTGCGGGCCCACCTCAAGCAG
GTGAAGAAGGAGGACACCGAGAAGGAAAACCGGGAGGTGGGAGACTGGCGGAAGAACATCGATGCACTGAGTGGAATGGAG
GGCCGCAAGAAAAAGTTTGAGAGCTGA
RGECO-TnI amino acid sequence
MVDSSRRKWNKAGHAVRAIGRLSSPVVSERMYPEDGALKSEIKKGLRLKDGGHYAAEVKTTYKAKKPVQLPGAYIVDIKLD
IVSHNEDYTIVEQCERAEGRHSTGGMDELYKGGTGGSLVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYE
AFQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYIKHPADIPDYFKLSFPEGFRWERVMNFEDGGIIHVNQDSSLQDGVFIY
KVKLRGTNFPPDGPVMQKKTMGWEATRDQLTEEQIAEFKEAFSLFDKDGDGTITTKELGTVMRSLGQNPTEAELQDMINEV
DADGDGTFDFPEFLTMMARKMNDTDSEEEIREAFRVFDKDGNGYIGAAELRHVMTDLGEKLTDEEVDEMIRVADIDGDGQV
NYEEFVQMMTAKLEMADGSSDAAREPRPAPAPIRRRSSNYRAYATEPHAKKKSKISASRKLQLKTLLLQIAKQELEREAEE
RRGEKGRALSTRCQPLELTGLGFAELQDLCRQLHARVDKVDEERYDIEAKVTKNITEIADLTQKIFDLRGKFKRPTLRRVR
ISADAMMQALLGARAKESLDLRAHLKQVKKEDTEKENREVGDWRKNIDALSGMEGRKKKFES.
Online Figure XI. DNA and amino acid sequence of RGECO-TnI. Sequence highlighted red is RGECO, blue is 
human cardiac TnI and black is a XhoI cloning site which corresponds to an additional LE linker sequence in the 
translated amino acid. 
GFP-TnT TnT-GFP GFP-TnI TnI-GFP GFP-TnC TnC-GFP
ΔpCa50  -0.031±0.018  -0.149±0.056 0.028±0.015  -0.279±0.624 0.564±0.269  -0.369±0.125 
ΔnH 0.980±0.691 7.308±3.703 0.505±1.085  -2.158±0.170 ** 0.8649±0.598  -0.867±0.912 
ΔMin (sec-1) 0.548±0.219 0.185±0.089 0.235±0.114 3.096±1.105 * 6.551±0.969 *** 5.382±1.874 *
ΔMax (sec
-1
) 0.686±0.588  -2.958±0.399 *  -0.036±0.270 0.787±0.457 1.479±0.798 1.439±0.545 *
Online Table I. Extracted parameters from in vitro actin activated acto-myosin S1 ATPase assays performed to 
investigate myofilament function in the presence of GFP conjugates of the troponin complex. Δ values from 
paired experimental comparisons for pCa50, nH, maximum and minimum activity (sec
-1) with standard error and 
significance. n=5, significance values comparing unconjugated with GFP conjugated troponin are p<0.001=***, 
p<0.01=** and p<0.05=* using a students t-test.
RGECO RGECO-TnT RGECO-TnI
K d at 25 °C (nM) 1607 1186 1105
K d at 37 °C (nM) 860 764 657
Quantum Yield pCa 4.5 (Φ) 0.20 0.33 0.3
Quantum Yield pCa 8.5 (Φ) 0.06 0.11 0.1
Molar Extinction coefficent pCa 4.5 (ε (mM-1•cm-1)) (565 nm) 32.39 34.53 35.87
Molar Extinction coefficent pCa 8.5 (ε (mM-1•cm-1)) (565 nm) 5.17 6.64 6.85
Molar Extinction coefficent pCa 4.5 (ε (mM-1•cm-1)) (455 nm) 4.16 6.18 6.2
Molar Extinction coefficent pCa 8.5 (ε (mM-1•cm-1)) (455 nm) 11.25 14.11 16.36
Brightness pCa 4.5 (mM-1•cm-1) 6.48 11.30 13.58
Brightness pCa 8.5 (mM-1•cm-1) 0.31 0.73 1.21
Intensity change ± Ca2+ 10.18x 10.33x 11.25x
Online Table II. Extracted parameters from fluorescence and absorbance spectra and kinetic experiments. 
Brightness is defined as the product of ε and Φ.
Online Table III. Extracted parameters of GPCM Ca2+ transients transduced with RGECO, RGECO-TnT or 
RGECO-TnI. Extracted values from a paired comparison of GPCMs adenovirally transduced with RGECO, RGECO-
TnT or RGECO-TnI.  n = total cell number from at least 3 separate cell isolations, ± = standard error. Significance 
values comparing RGECO to RGECO-TnT or RGECO-TnI are p<0.01 = ** and p<0.001 = ***. RGECO-TnT verses 
RGECO-TnI = ns for all parameters, using a Kruskal Wallis non parametric test. 
Sensor n
Time to 50%
Ca2+ Binding
(sec)
Time to 50%
Ca2+ Release
(sec)
RGECO 108 0.058±0.003 0.308±0.012
RGECO-TnT 55 0.105±0.007 *** 0.282±0.011 **
RGECO-TnI 112 0.097±0.004 *** 0.267±0.006 ***
Online Table IV. Extracted parameters of GPCMs transduced with RGECO or myofilament localised RGECO 
and WT/HCM mutant troponin. Extracted Ca2+ transient values from GPCMs adenovirally transduced with RGECO 
(A) or RGECO-TnI/RGECO-TnT (B) and either WT cTnT, cTnT R92Q, WT cTnI, or cTnI R145G.  n = total cell 
number from at least 3 separate cell isolations, ± = standard error. Significant values comparing either WT cTnT to 
cTnT R92Q or WT cTnI to cTnI R145G are p<0.001 = ***, or p<0.01 = ** using a Mann Whitney test.
Sensor Mutant n
Relative RGECO 
Peak Intensity
Time to 50%
Ca2+ Binding
(sec)
Time to 50%
Ca2+ Release
(sec)
Time of Peak 
(sec)
RGECO WT cTnT 94 1.00±0.041 0.066±0.002 0.219±0.006 0.288±0.007
RGECO cTnT R92Q 94 0.99±0.045 0.102±0.004 *** 0.247±0.006 ** 0.365±0.007 ***
RGECO WT cTnI 107 1.00±0.037 0.070±0.002 0.198±0.004 0.281±0.006
RGECO cTnI R145G 103 1.60±0.058 *** 0.083±0.002 *** 0.255±0.005 *** 0.345±0.008 ***
Sensor Mutant n
Relative RGECO 
Peak Intensity
Time to 50%
Ca2+ Binding
(sec)
Time to 50%
Ca2+ Release
(sec)
Time of Peak 
(sec)
RGECO-TnI WT cTnT 102 1.00±0.039 0.087±0.003 0.194±0.004 0.333±0.007
RGECO-TnI cTnT R92Q 115 1.32±0.053 *** 0.128±0.005 *** 0.247±0.004 *** 0.424±0.008 ***
RGECO-TnT WT cTnI 123 1.00±0.030 0.082±0.003 0.202±0.005 0.338±0.008
RGECO-TnT cTnI R145G 127 1.16±0.042 ** 0.094±0.003 ** 0.247±0.005 *** 0.391±0.010 ***
A
B
